Rivenprost  (Synonyms: ONO-4819; ONO-AE1-734)

Rivenprost (ONO-4819; ONO-AE1-734) is a selective agonist for prostaglandin E receptor EP4 with K_i of 0.7 nM. Rivenprost exhibits hepatoprotective and bone anabolic effects^[1][2].

Rivenprost (1 nM–1 μM) stimulates the osteoblast differentiation through upregulation of Runx2 and Osterix, leading to increased bone formation^[1].
Rivenprost (1 nM–1 μM) inhibits the adipocytes differentation in bone by downregulating the mRNA expression of PPARγ^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Rivenprost (10 μg/kg, s.c. for 5 weeks) increases bone formation and decreases levels of age-dependent adipocytes in Sprague-Dawley rats^[1].
Rivenprost (0.2 mg/kg, i.p., single dosage) exhibits hepatoprotective efficacy towards GalN-/LPS-induced liver injury in wistar rats through inflammatory cytokines such as TNF-α^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

450.59

C₂₄H₃₄O₆S

256382-08-8

COCC1=CC=CC(C[C@H](O)/C=C/[C@@H]2[C@H](C(C[C@H]2O)=O)CCSCCCC(OC)=O)=C1

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ninomiya T, et al., Prostaglandin E(2) receptor EP(4)-selective agonist (ONO-4819) increases bone formation by modulating mesenchymal cell differentiation. Eur J Pharmacol. 2011 Jan 10;650(1):396-402.  [Content Brief]

  [2]. Kasai K, et al., A novel prostaglandin E receptor subtype agonist, 0N0-4819, attenuates acute experimental liver injury in rats. Hepatol Res. 2001 Nov;21(3):252-260.  [Content Brief]